Abstract
Advances in medicines have increased the effectiveness of treatments and the social and cultural authority of doctors. However, as prescribing has become the dominant modality of treatment, the “pharmaceuticalization” of medical practice has often resulted in treatment “at a distance”, with doctors having limited contact with patients. Older and poorer people, who are socially distanced from medical prescribers, suffer more adverse drug reactions (ADRs) than the general population. A team approach to checking patients systematically for ADRs, as detailed in manufacturers’ literature, can minimise medication errors, but regular review is rare. This paper explains the benefits of medicines monitoring to protect older patients from iatrogenic harm, such as over-sedation, falls, or drug-induced Parkinsonism. We show how multidisciplinary initiatives to optimise prescribing can be supported by using a recognised resource—the adverse drug reaction profile (ADRe). The profile identifies and documents patients’ signs and symptoms of putative ADRs. Better monitoring allows professionals to adjust prescribing and respond to identified problems with agility. Implementation of systematic monitoring will require changes to the regulatory regime and better inter-professional cooperation. Providing carers, nurses and pharmacists with a structured system to monitor patients would democratise relevant medical knowledge and help address ageism and the socio-economic health divide.
Subject
Geriatrics and Gerontology,Gerontology,Ageing,Health(social science)
Reference72 articles.
1. The Impact of New Medicines in the NHS: 70 Years of Innovation. OHE Consulting Reporthttps://www.ohe.org/publications/impact-new-medicines-nhs-70-years-innovation
2. The therapeutic revolution
3. Iatrogenic disease: A hazard of multiple drug therapy;D’Arcy;R. Soc. Health J.,1976
4. IATROGENESIS IN THE ELDERLY: Drug-Related Problems
5. Guideline on Good Pharmacovigilance (GVP)-Module VI–Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev 2)http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/08/WC500232767.pdf
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献